Laurus Labs Ltd, based in India, is a pharmaceutical company that stands out with its certifications from FDA and EDQM.
One of their notable products is EFAVIRENZ USP, with a corresponding US DMF Number 21964.
Remarkably, this DMF maintains an Active status since its submission on September 10, 2008, highlighting commitment to regulatory compliance.
Their GDUFA DMF Review was successfully complete, with a review date of January 31, 2013, and payment made on January 11, 2013, indicating their dedication to facilitating drug approvals, Categorized as Type II